RESUMEN
BACKGROUND AND OBJECTIVES: To evaluate a regimen of induction and consolidation chemotherapy, followed by a post-remission therapy which depended on age and cytogenetics, in patients with primary acute myeloid leukemia. DESIGN AND METHODS: Two hundred patients up to 60 years old received idarubicin, standard dose cytarabine and etoposide as induction chemotherapy and one consolidation course including intermediate dose cytarabine and mitoxantrone. Subsequently, patients with favorable cytogenetics, [i.e., t(8;21), inv(16)] were scheduled to receive 2 courses of high-dose cytarabine. The remainder were scheduled for allogeneic stem cell transplantation (SCT), if Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico
, Leucemia Mieloide Aguda/tratamiento farmacológico
, Leucemia Mieloide Aguda/terapia
, Trasplante de Células Madre
, Adolescente
, Adulto
, Citarabina/administración & dosificación
, Esquema de Medicación
, Etopósido/administración & dosificación
, Femenino
, Prueba de Histocompatibilidad
, Humanos
, Leucemia Mieloide Aguda/clasificación
, Leucemia Mieloide Aguda/inmunología
, Leucemia Mieloide Aguda/mortalidad
, Masculino
, Persona de Mediana Edad
, Probabilidad
, Estudios Prospectivos
, Análisis de Supervivencia
, Acondicionamiento Pretrasplante
RESUMEN
We present the case of a man affected by an unclassified mature B-cell neoplasm with a bone marrow culture stimulated with TPA showing a 46,XY, t(11;13)(q13;q14)[14]/46,XY [6] karyotype. Fluorescent in situ hybridization demonstrated that the BCL1 oncogene is translocated (not rearranged) to chromosome band 13q14 and that a copy of D13S319 locus is deleted. To our knowledge, this is the first reported case with this novel cytogenetic aberration.